How could Amgen's cost-effectiveness trial results affect Medicare's coverage decisions?
Repatha's cost-effectiveness finding may support favorable coverage decisions by Medicare. The Duke-led analysis of Amgen's Repatha drug found it to be cost-effective for high-risk adults who have never had a heart attack or stroke. Specifically, the analysis showed the drug costs about 36% below the 2025 American Heart Association and American College of Cardiology benchmark of $120,000 per Quality-Adjusted Life Year (QALY). As a major payer, Medicare uses such cost-effectiveness ratios to determine if a treatment's value justifies its cost, which could potentially lead to favorable reimbursement or coverage decisions for Repatha.
- Effect
- Mild positive
- How direct
- Brind's reasoning
- When
- Within months
- The story
- No new developments lately
How it reaches Medicare
-
Amgen announced results from the VESALIUS-CV trial, presenting a health economic analysis of its cholesterol drug Repatha. The analysis found Repatha to be cost-effective for high-risk adults who have never had a heart attack or stroke. This cost was approximately 36% below a benchmark used by the American College of Cardiology and American Heart Association. The analysis was led by the Duke Clinical Research Institute in collaboration with Mass General Brigham and Harvard.
The full event1independent outlet -
Medicare, as a major federal health insurer, relies on cost-effectiveness studies to evaluate the value of pharmaceutical treatments. A finding that a drug is significantly below the established cost-per-QALY threshold provides a strong data point that could support favorable payment structures or coverage rules for the drug.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
US federal health insurance
Everything about Medicare
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The analysis found Repatha cost-effective for high-risk adults who have never had a heart attack or stroke.medicaldaily.com
- The drug costs about 36% below a benchmark used by the American College of Cardiology and American Heart Association.medicaldaily.com
- The 2025 AHA and ACC cost and value statement sets $120,000 per QALY as that threshold.medicaldaily.com
- Repatha cut the combined risk of coronary heart disease death, heart attack or ischemic stroke by 25% over a median of about 4.6 years.medicaldaily.com
Why it matters
For Medicare and other major payers, the cost-effectiveness of high-value drugs is critical to managing national healthcare spending. If a drug like Repatha can demonstrate significant clinical benefit while remaining substantially below the established cost-per-QALY threshold, it strengthens the case for broad inclusion in covered formularies and favorable reimbursement rates.
This finding adds to the growing trend of using health economic data to guide policy, moving away from simple price negotiations toward value-based care models. The outcome could influence how Medicare structures payments for advanced cholesterol therapies, potentially increasing patient access while maintaining fiscal control.
What we don't know yet
- Will Medicare require the full analysis to be published in a peer-reviewed journal before making a coverage decision?
- How will the specific cost-effectiveness ratio be weighed against the drug's list price and current coverage status?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- medicaldaily.comTuesday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.